A randomized phase II study to explore the efficacy and feasibility of upfront rotations between sunitinib and everolimus versus sequential treatment of first line sunitinib and second line everolimus until progression in patients with metastatic clear cell renal cancer. - SUNRISES
100 项与 APRO Co., Ltd. 相关的临床结果
0 项与 APRO Co., Ltd. 相关的专利(医药)
100 项与 APRO Co., Ltd. 相关的药物交易
100 项与 APRO Co., Ltd. 相关的转化医学